RECRUITING

Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic cancer and caregivers by proxy (legal representative). Thoracic cancer occurs in the chest and often causes symptoms for patients. Patients and/or their caregivers are often unable to attend in-person clinic visits for various reasons. The most frequently reported symptom by patients at initial palliative care consultations is pain, and caregivers' most common concerns are pain management for the patient, stress reduction, and fears about patient decline. Earlier palliative care referral can help control these symptoms before they worsen, providing a better quality of life for patients and caregivers. improve physical and emotional functioning for patients and caregivers in cancer care. This study may help researchers learn how an electronic symptom monitoring program may provide an earlier and more accessible way for patients with thoracic cancer to receive palliative care.

Official Title

SyMPLER: Patient- and Caregiver-Triggered Palliative Referrals Via an Electronic Symptom Monitoring Program

Quick Facts

Study Start:2024-02-09
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06396598

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * PATIENTS: Age ≥ 18 years
  2. * PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy
  3. * PATIENTS: ≥ 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic
  4. * PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment
  5. * PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
  6. * PATIENTS: Ability to read and understand English
  7. * PATIENTS: Access to a device with email or text messaging capability
  8. * CAREGIVERS: Age ≥ 18 years
  9. * CAREGIVERS: Identified by patient participant as primary caregiver
  10. * CAREGIVERS: Corresponding patient participant has consented to participate in the study
  11. * CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
  12. * CAREGIVERS: Ability to read and understand English
  13. * CAREGIVERS: Access to a device with email or text messaging capability
  1. * PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation
  2. * PATIENTS: Prisoners are excluded from participation
  3. * PATIENTS: Pregnant patients are excluded from participation
  4. * PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist are excluded from participation
  5. * PATIENTS: There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, prior cancer diagnoses, presence of comorbidities or brain metastases

Contacts and Locations

Study Contact

The Ohio State Comprehensive Cancer Center
CONTACT
800-293-5066
OSUCCCClinicaltrials@osumc.edu

Principal Investigator

Julia L Agne, MD
PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center

Study Locations (Sites)

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Julia L Agne, MD, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-09
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2024-02-09
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Malignant Thoracic Neoplasm